04th week of 2012 patent applcation highlights part 37 |
Patent application number | Title | Published |
20120020946 | Methods for Inactivating Viruses - The present invention provides a method for inactivating viruses, by contacting the viruses with a haloperoxidase, hydrogen peroxide, chloride ions, bromide ions, and ammonium ions. | 2012-01-26 |
20120020947 | COMPOSITIONS AND METHODS FOR INCREASING LEAN MUSCLE MASS AFTER EXERCISE - The present invention relates to novel methods and compositions comprising casein, creatine or derivatives of creatine, branched chain amino acids and proteases useful for increasing lean muscle mass after exercise. | 2012-01-26 |
20120020948 | DAG-TYPE AND INDIRECT PROTEIN KINASE C ACTIVATORS AND ANTICOAGULANT FOR THE TREATMENT OF STROKE - The present disclosure provides a method for treating stroke by administering an anticoagulant, e.g., recombinant tissue plasminogen activator (rTPA), and a protein kinase C (PKC) activator, wherein the PKC activator may be administered before, after, or at the same time as the rTPA. The methods disclosed herein may limit the size of infarction and/or reduce mortality, the disruption of the blood-brain barrier, and/or the hemorrhagic damage due to ischemic stroke compared with rTPA administration alone; and may also extend the therapeutic time window for administering rTPA after a stroke. Also disclosed are compositions and kits comprising rTPA and a PKC activator for treating stroke. | 2012-01-26 |
20120020949 | MHC-LESS cells - The present disclosure relates to compositions, methods, systems, computer-implemented methods, and computer program products thereof that relate to biological cells for delivery of at least one therapeutic agent to a biological tissue or subject. | 2012-01-26 |
20120020950 | ANTIBACTERIAL COMPOUNDS - Disclosed are compounds of formula (I), which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by, | 2012-01-26 |
20120020951 | Adverse side-effects associated with administration of anti-hyaluronan agents and methods for ameliorating or preventing the side-effects - Provided herein are methods for ameliorating an adverse effect of systemic administration of a PEG hyaluronan degrading enzyme to a subject. The methods involve systemically administering a PEGylated hyaluronan degrading enzyme, particularly a PEGylated hyaluronidase, such as any of the animal or bacterial hyaluronidases, to the subject and administering an amount of a corticosteroid sufficient to ameliorate the adverse effect. Also provided are method of treating a hyaluronan-associated disease or condition for single-agent therapy or combination therapy. | 2012-01-26 |
20120020952 | METHODS FOR PRODUCING MIXTURES OF ANTIBODIES - The invention relates to a method for producing a mixture comprising two or more different antibodies in a single recombinant host cell. In one embodiment, a mixture of different monovalent antibodies is produced. In another embodiment, a mixture of monovalent and bivalent antibodies is produced. The invention also relates to mixtures of antibodies obtainable by the method of the invention and to light chain sequences that are particularly useful in the method of the invention. | 2012-01-26 |
20120020953 | DIAGNOSIS AND TREATMENT OF CANCER - Provided herein are methods for diagnosing cancer by determining the level of expression of SETDB1 in a biological sample. Also provided herein are methods for treating cancer by administering an inhibitor of SETDB1 to a subject in need thereof. | 2012-01-26 |
20120020954 | METHODS OF PREDICTING CLINICAL COURSE AND TREATING MULTIPLE SCLEROSIS - Provided are methods and kits for classifying a subject as being more likely to have benign multiple sclerosis (BMS) or as being more likely to have typical relapsing remitting multiple sclerosis (RRMS). Classification of multiple sclerosis disease course is performed by comparing a level of expression of at least one gene involved in the RNA polymerase I pathway in a cell of the subject to a reference expression data of said at least one gene obtained from a cell of at least one subject pre-diagnosed as having BMS and/or from a cell of at least one subject pre-diagnosed as having typical RRMS, thereby classifying the subject as being more likely to have BMS or as being more likely to have typical RRMS. Also provided are methods of diagnosing and treating multiple sclerosis and methods of monitoring treatment efficiency. | 2012-01-26 |
20120020955 | Detection of Neurological Disorders With Immune Reactions - The present invention relates generally to the field of methods of diagnosing a neurological disorder with immune reaction in a mammal. Also disclosed are methods of treating and/or preventing a neurological disorder with immune reaction in a patient. | 2012-01-26 |
20120020956 | ACTIVATION OF SODIUM POTASSIUM ATPASE - Activation sites on the alpha subunit of sodium potassium ATPase have been discovered. It has also been discovered that certain antibodies that bind to the alpha subunit of sodium potassium ATPase dramatically increase enzyme activity. There has never before been a report of precise activation sites or drug interaction sites for sodium potassium ATPase. Certain methods have also been discovered for treating or preventing diseases associated with low sodium potassium ATPase activity by administering antibodies, antibody fragments and small molecules that bind to the activation sites on the alpha subunit of sodium potassium ATPase. | 2012-01-26 |
20120020957 | DENGUE VIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF - The invention relates to antibodies and antigen binding fragments thereof and to cocktails of antibodies and antigen binding fragments that neutralize dengue virus infection without contributing to antibody-dependent enhancement of dengue virus infection. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antigen binding fragments. In addition, the invention relates to the use of the antibodies, antigen binding fragments, and epitopes in screening methods as well as in the diagnosis and therapy of dengue virus infection. | 2012-01-26 |
20120020958 | FIBCD1 FOR THE PREVENTION AND TREATMENT OF DISEASES - The present invention relates to methods and compositions for the treatment and/or prevention of diseases such as allergic diseases and inflammatory bowel diseases comprising one or more FIBCD1 binding molecules or pharmaceutically acceptable salts, esters, and amides thereof and optionally one or more non-FIBCD1 binding molecules or pharmaceutically acceptable salts, esters, and amides thereof; as well as the use of such pharmaceutical composition for the prevention and/or treatment of diseases such as allergic diseases and inflammatory bowel diseases. FIBCD1 is herein defined as either a transmembrane receptor, the corresponding DNA or the corresponding mRNA as defined by SEQ ID No. 1, 2 and 3 as well as homologous thereof. | 2012-01-26 |
20120020959 | USE OF THE SPARC MICROENVIRONMENT SIGNATURE IN THE TREATMENT OF CANCER - The invention provides multiparametric anti-SPARC antibody-based techniques for predicting the response to chemotherapy. | 2012-01-26 |
20120020960 | Thymic Stromal Lymphopoietin (TSLP) and OX40 Ligand in Cancer - Compositions and methods for an immunotherapeutic approach for human breast cancer is provided herein. Any antagonist of thymic stromal lymphopoietin (TSLP) and/or OX40L to inhibit tumor development and IL-13 secretion by blocking the upregulation of OX40L by DCs exposed to breast cancer, thereby blocking their capacity to generate inflammatory IL-13 | 2012-01-26 |
20120020961 | METHODS AND COMPOSITIONS FOR LIVER CANCER THERAPY - The present disclosure provides methods of treating liver cancer and preventing liver cancer recurrence with anti-progastrin antibodies, methods of monitoring treatment efficacy of anti-progastrin therapy for liver cancer, and compositions useful therefore. | 2012-01-26 |
20120020962 | METHOD OF DEPLETING REGULATORY T CELL - The present invention relates to the method for depleting in vivo regulatory T cell, the method for suppressing IL-10 producing activity of regulatory T cell, the method for treating diseases in which pathologic conditions are deteriorated by regulatory T cell and the method for enhancing tumor immunity which comprises administering to a patient a monoclonal antibody which specifically binds to human CC chemokine 4 (CCR4) or the antibody fragment thereof. | 2012-01-26 |
20120020963 | ANTI-INTEFERON ALPHA MONOCLONAL ANTIBODIES AND METHODS FOR USE - The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease. | 2012-01-26 |
20120020964 | Antibodies for Norovirus - Norovirus antigen peptides are described having an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-16, or fragments thereof. Such peptides can be used in the preparation of antiviral therapies such as vaccines, methods of preparing antibodies to the antigen peptides, methods of using the peptides or the corresponding antibodies for detection of norovirus, and compositions of the peptides, DNA and/or antibodies. A kit for the detection of norovirus is also provided. | 2012-01-26 |
20120020965 | Molecules that bind CD180, compositions and methods of use - The present invention provides novel CD180 binding molecules, methods for their identification, and methods for their use. | 2012-01-26 |
20120020966 | Multispecific antibody targeting and multivalency through modular recognition domains - Antibodies containing one or more modular recognition domains (MRDs) that can be used to target the antibodies to specific sites are described. The use of antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also described. | 2012-01-26 |
20120020967 | VEGF antibodies comprising modular recognition domains - Antibodies containing one or more modular recognition domains (MRDs) that can be used to target the antibodies to specific sites are described. The use of antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also described. | 2012-01-26 |
20120020968 | Chimeric DRG11-Responsive (DRAGON) Polypeptides - This invention features methods and compositions useful for treating and diseases caused by a dysregulation of the BMP/GDF branch of the TGF-β signaling pathway. Also disclosed are methods for identifying compounds useful for such therapy. | 2012-01-26 |
20120020969 | Compositions And Methods For Inhibiting Viral Adhesion - The present invention provides compositions and methods for treating or preventing viral infections. | 2012-01-26 |
20120020970 | METHODS OF EVALUATING PATIENTS - Methods of treating patients and evaluating patients for disease stage and/or severity are disclosed. | 2012-01-26 |
20120020971 | ANTIBODIES USEFUL IN PASSIVE INFLUENZA IMMUNIZATION - Monoclonal antibodies and fragments thereof that are crossreactive with multiple clades of influenza virus including both Group 1 and Group 2 representatives are disclosed. These antibodies are useful in controlling influenza epidemics and pandemics as well as in providing prophylactic or therapeutic protection against seasonal influenza. | 2012-01-26 |
20120020972 | ANTIBODIES RELATING TO PIVKA-II AND USES THEREOF - The present disclosure relates to antibodies and immunoassay methods for use in the diagnosis, treatment and prevention of hepatocellular carcinoma (HCC), liver cancer and related conditions. | 2012-01-26 |
20120020973 | CHIMERIC OSPA GENES, PROTEINS, AND METHODS OF USE THEREOF - The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of | 2012-01-26 |
20120020974 | OPTIMIZING ERYTHROPOIETIN THERAPY - The methods described herein can be used to identify ex ante which hemodialysis patients are likely to develop EPO resistance and therefore will require additional rHu EPO, and to provide treatments that can reduce the need for additional rHu EPO. In addition, the methods can be used to predict which subjects have a higher risk of mortality, to identify high-risk patients who can then be monitored more closely or treated more aggressively. Also provided are kits for carrying out the described methods. | 2012-01-26 |
20120020975 | ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) - Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described. | 2012-01-26 |
20120020976 | ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) - Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described. | 2012-01-26 |
20120020977 | PANCREATIC CANCER GENES - The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia. | 2012-01-26 |
20120020978 | ANTIBODIES AGAINST FATTY ACID SYNTHASE - The present invention relates to antibodies that immunospecifically bind to FAS and certain FAS related proteins. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to FAS-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed. | 2012-01-26 |
20120020979 | METHODS FOR TREATING IgE-MEDIATED DISORDER - This invention relates to methods of treating IgE mediated disorders such as allergy and asthma based on activating surface-bound IgD molecules on basophils. The invention also relates to methods of making IgD, as well as methods of screening for antimicrobial agents from IgD-activated basophils. | 2012-01-26 |
20120020980 | HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN CYTOMEGALOVIRUS (CMV) GB PROTEIN - Antibodies to human Cytomegalovirus (CMV) gB protein have been isolated from human B cells. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy. | 2012-01-26 |
20120020981 | Anti-IL6/IL-6R Antibodies and Methods of Use Thereof - This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic. | 2012-01-26 |
20120020982 | FORMULATIONS AND TREATMENTS FOR TRICHOLOGY - A formulation for trichological treatment of a patient including, in a dosage in the range of 3 g to 8 g: phytosterols in the range of 200 mg to 2500 mg; the quantitative equivalent of | 2012-01-26 |
20120020983 | EMP2 ANTIBODIES AND THEIR THERAPEUTIC USES - The present invention provides methods and compositions useful in the treatment or prevention of | 2012-01-26 |
20120020984 | Genetic Markers for Predicting Responsiveness to Combination Therapy - The invention provides compositions and methods for determining the likelihood of successful treatment with an effective amount of an anti-VEGF antibody or equivalent thereof, in combination with anti-EGFR antibody or equivalent thereof, and, in some aspects in combination with a topoisomerase inhibitor. The methods comprise determining the identity of a gene of interest in a patient sample and correlating the patient's genotype with the predictive response. Patients identified as responsive are then treated with the appropriate therapy. | 2012-01-26 |
20120020985 | ANTIBODIES AGAINST IL-17BR - The invention provides the antibody D9.2 and antibody molecules based on D9.2 which bind interleukin-17 receptor B. These may be useful in therapy, e.g. the treatment of asthma, ulcerative colitis or Crohn's disease. | 2012-01-26 |
20120020986 | Antibodies to the PcrV Antigen of Pseudomonas aeruginosa - The current invention provides high-affinity antibodies to the | 2012-01-26 |
20120020987 | MHC-Less cells - The present disclosure relates to compositions, methods, systems, computer-implemented methods, and computer program products thereof that relate to biological cells for delivery of at least one therapeutic agent to a biological tissue or subject. | 2012-01-26 |
20120020988 | Antibodies specifically binding to human TSLPR and methods of use - An antibody specifically binding to human thymic stromal lymphopoietin receptor (TSLPR), characterized in comprising as heavy chain variable domain CDR regions a CDR1 region of SEQ ID NO:2 or 17, a CDR2 region of SEQ ID NO:3 or 10, and CDR3 region of SEQ ID NO:4, and as light chain variable domain CDR regions a CDR1 region of SEQ ID NO:6 or 12, a CDR2 region of SEQ ID NO:7, 13 or 15, and a CDR3 region of SEQ ID NO:8. is useful for the treatment of immunological diseases. | 2012-01-26 |
20120020989 | METHODS OF TREATING COLORECTAL CANCER - The present invention provides a pharmaceutical composition and a treating method for colorectal cancer which is difficult for a surgical treatment, comprising an anti-A33 human antibody and a chemotherapy agent in combination. Based on the present invention, a pharmaceutical composition and a treating method comprising the combination of anti-A33 human antibody with CPT-11 (irinotecan) can exhibit a certain degree of antitumor effect on a patient with colorectal cancer who is found recurrence after previously-initiated therapy and/or a patient with colorectal cancer who is difficult to be cured by existing treatments for colorectal cancer. | 2012-01-26 |
20120020990 | ISOLATED MAMMALIAN MONOCYTE CELL GENES; RELATED REAGENTS - Nucleic acids encoding various monocyte cell proteins from a primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided. | 2012-01-26 |
20120020991 | PRODOMAIN MODULATORS OF ADAM 10 - The presently disclosed subject matter discloses isolated ADAM 10 modulating peptides and related compounds useful for studying the biological functions of ADAM 10 and for the treatment of diseases such as cancer, neurological disorders, asthma, and allergic responses, and disorders characterized at least in part by the presence of one or more of inflammation, excess cell proliferation, angiogenesis, and excess soluble CD23. In one aspect, the presently disclosed subject matter provides isolated mouse and human ADAM 10 prodomain comprising the sequence set forth in SEQ ID NOs 1-8, or a sequence having at least 95% homology to any of SEQ ID NOs 1-8 and having the functionality of modulating ADAM 10 activity. | 2012-01-26 |
20120020992 | Production of Biologically Active Proteins - A fusion protein that is expressed in a recombinant protein body-like assembly (RPBLA) in host eukaryotic cells and organisms is disclosed. More particularly, a biologically active polypeptide fused to a protein sequence that mediates the induction of RPBLA formation is expressed and accumulated in host cells after transformation with an appropriate vector. The eukaryotic host cell does not produce protein bodies in the absence of the fusion protein. Methods for preparing and using the RPBLAs and the fusion protein are also disclosed, as are nucleic acid molecules that encode the fusion proteins. | 2012-01-26 |
20120020993 | VACCINE - The present invention relates to a pharmaceutical formulation comprising lipopolysaccharide derived from | 2012-01-26 |
20120020994 | MULTIVALENT, DRYING RESISTANT, EVOLUTION-BASED VACCINES - Disclosed is a recombinant nonpermutated bacteriophage that includes a nucleic acid sequence that is at least 150 kb in length wherein the bacteriophage is made to display one or more surface antigens such as heterologous polypeptides, and compositions and kits that include the recombinant nonpermutated bacteriophages of the present invention. Also disclosed are methods of inducing an immune response in a subject that involve administration of a pharmaceutically effective amount of a composition comprising the recombinant nonpermutated bacteriophages of the present invention. | 2012-01-26 |
20120020995 | PARAPOXVIRUS VECTORS - The present invention relates to recombinant parapoxviruses comprising heterologous DNA derived from a canine distemper virus, to the preparation of such constructs, and to their use in immunogenic compositions and vaccines. It further relates to the use of recombinant parapoxviruses for diagnostics. | 2012-01-26 |
20120020996 | VACCINES AGAINST CLOSTRIDIUM DIFFICILE AND METHODS OF USE - Attenuated microorganisms expressing | 2012-01-26 |
20120020997 | MULTI PLASMID SYSTEM FOR THE PRODUCTION OF INFLUENZA VIRUS - Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. | 2012-01-26 |
20120020998 | PLASMACYTOID DENDRITIC CELL LINE USED IN ACTIVE OR ADOPTIVE CELL THERAPY - The present invention relates to a method for inducing and amplifying specific effectors, which comprises obtaining pulsed plasmacytoid dendritic cells (pDC) by incubation of a pDC line with at least one antigen, the pulsed pDC being subsequently irradiated and brought into contact with peripheral blood mononuclear cells (PBMC), and cultured or injected into an organism. The pulsed and irradiated pDC and the PBMC share at least one major histocompatibility complex (MHC) allele. | 2012-01-26 |
20120020999 | DNA Vaccine Compositions with HIV/SIV Gene Modifications - The present invention is directed to a DNA vaccine for immunization against HIV. The invention comprises a DNA molecule that has a sequence encoding a plurality of viral proteins capable of stimulating an immune response against HIV. The DNA molecule is rendered safe for use as a vaccine by the disruption of genes encoding reverse transcriptase, integrase, and Vif. The DNA molecule is further rendered safe by at least a partial deletion of the 3′ LTR. | 2012-01-26 |
20120021000 | HIV DNA Vaccine Methods of Use - The present invention is directed to a DNA vaccine for immunization against HIV. The invention comprises a DNA molecule that has a sequence encoding a plurality of viral proteins capable of stimulating an immune response against HIV. The DNA molecule is rendered safe for use as a vaccine by the disruption of genes encoding reverse transcriptase, integrase, and Vif. The DNA molecule is further rendered safe by at least a partial deletion of the 3′ LTR. | 2012-01-26 |
20120021001 | MARKED BOVINE VIRAL DIARRHEA VIRUS VACCINES - The present invention is directed to a bovine viral diarrhea virus comprising at least one helicase domain amino acid mutation wherein the mutation in the NS3 domain results in a loss of recognition by a monoclonal antibody raised against wild-type NS3 but wherein viral RNA replication and the generation of infectious virus is retained. The present invention is useful, for example, to produce a marked bovine viral diarrhea virus vaccine or to differentiate between vaccinated and infected or unvaccinated animals. | 2012-01-26 |
20120021002 | GENETICALLY ENGINEERED CLOSTRIDIAL GENES, PROTEINS ENCODED BY THE ENGINEERED GENES, AND USES THEREOF - The present invention relates to an isolated Clostridial neurotoxin propeptide having a light chain region, a heavy chain region, where the light and heavy chain regions are linked by a disulfide bond, and an intermediate region connecting the light and heavy chain regions. An isolated nucleic acid molecule encoding a Clostridial neurotoxin propeptide is also disclosed. Also disclosed is an isolated, physiologically active Clostridial neurotoxin produced by cleaving a Clostridial neurotoxin propeptide, a vaccine or antidote thereof, and methods of immunizing against or treating for toxic effects of Clostridial neurotoxins. Methods of expressing recombinant physiologically active Clostridial neurotoxins are also disclosed. Also disclosed is a chimeric protein having a heavy chain region of a Clostridial neurotoxin and a protein with therapeutic functionality. A treatment method is also disclosed. | 2012-01-26 |
20120021003 | VACCINE FOR PROTECTION AGAINST STREPTOCOCCUS SUIS BACTERIA OF VARIOUS SEROTYPES - The present invention pertains to the use of | 2012-01-26 |
20120021004 | MEDIUM AND METHOD OF DERIVING AND USING A MUTATED BACTERIA STRAIN - A new strain of | 2012-01-26 |
20120021005 | MYCOPLASMA GALLISEPTICUM FORMULATION - The present invention provides a formulation that prevents virulent | 2012-01-26 |
20120021006 | EGFR-HOMING DOUBLE-STRANDED RNA VECTOR FOR SYSTEMIC CANCER TREATMENT - An epidermal growth factor receptor (EGFR)-homing vector comprising a double-stranded RNA (dsRNA) molecule with an EGFR-binding peptide or polypeptide, is disclosed for use in combination with immune cells for treatment of cancer overexpressing EGFR. | 2012-01-26 |
20120021007 | NITRIC OXIDE FUROXAN DERIVATIVE COMPOUNDS ENDOWED WITH ANTITUMORAL ACTIVITY - The present invention relates to nitric oxide furoxan derivative compounds which showed to be active in the treatment of tumors. In addition, they may be used as adjuvants in cancer immunotherapy. | 2012-01-26 |
20120021008 | INJECTABLE AND MOLDABLE CERAMIC MATERIALS - Disclosed is an injectable and moldable ceramic material comprising porous calcium phosphate having surface-microporosity, and a water-free carrier, wherein the carrier is selected so as to disintegrate under physiological circumstances. The latter refers to the property of a carrier to dissolve, disassociate, or otherwise disintegrate after placement (e.g. through injection or implantation) into the human body. By selection of a water-free polymer or polymer blend which is combined with surface-microporous calcium phosphates, the favourable osteoinductive properties by virtue of the surface-microporosity can be retained for prolonged shelf life. | 2012-01-26 |
20120021009 | PROCESS FOR MAKING GASTRORETENTIVE DOSAGE FORMS - The present disclosure relates to a novel process for making oral solid gastro-retentive forms, including the steps of providing a powder mixture including a hydrophobic powder, overgranulating this powder mixture with a granulating solution into an overgranulated paste, and drying all paste into a solid, as well as to pharmaceutical solid dosage forms which are retained in the stomach or upper gastrointestinal tract for a controlled delivery of a drug. | 2012-01-26 |
20120021010 | ANTIPLATELET AGENT AND METHODS OF USING THE SAME - Disclosed herein are compositions and methods for inhibiting platelet aggregation in a patient in need thereof. The compositions and methods use superparamagnetic iron oxide nanoparticles (SPIONs), which are shown to inhibit aggregation of platelets. Such methods are useful in preventing blood clotting in diseases such as acute coronary syndrome. Also disclosed are in vitro methods of sensing platelet function using SPIONs. | 2012-01-26 |
20120021011 | ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITION COMPRISING EXTRACTS FROM BROUSSONETIA PAPYRIFERA AND LONICERA JAPONICA - The present invention relates to a pharmaceutical composition for alleviating or treating inflammations and/or pains, the pharmaceutical composition comprising extracts from | 2012-01-26 |
20120021012 | NOVEL PHARMACEUTICAL USES FOR NANOPARTICLES - The present invention relates to SiC nanoparticles to be used in the context of cancer treatment, said nanoparticles preferably having a size less than 100 nm. | 2012-01-26 |
20120021013 | Composition Containing Sulfoalkyl Ether Cyclodextrin and Latanoprost - An aqueous composition of latanoprost and SAE-CD is provided. The composition possesses improved stability over otherwise similar compositions excluding SAE-CD. Methods of and systems for treating diseases, disorders, conditions or symptoms of the eye that are therapeutically responsive to latanoprost are also provided. | 2012-01-26 |
20120021014 | CORROSION CURRENT-GENERATING METAL PARTICULATES AND USE THEREOF - Metal particulates capable of generating low levels of corrosion current beneficial for pharmaceutical, cosmetic and other medical uses are provided. | 2012-01-26 |
20120021015 | CROSSLINKED FIBERS AND METHOD OF MAKING SAME USING UV RADIATION - Cross-linked fibers include first and second precursors, each possessing a core and at least one functional group known to have click reactivity when exposed to UV radiation. Mixtures of the first and second precursors are extruded to produce a filament and irradiated with UV light during the extrusion process. | 2012-01-26 |
20120021016 | NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM - Compounds of general Formula (I), | 2012-01-26 |
20120021017 | N-PHENYLACETAMIDE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM - Compounds of general Formula (I), | 2012-01-26 |
20120021018 | MICROSPHERES FOR THE SUSTAINED RELEASE OF OCTREOTIDE WITH A LOW INITIAL BURST - This disclosure features microspheres and a method of making them. The microspheres are for sustained release of an octreotide compound with a low initial burst, comprising a poly(D,L-lactide-co-glycolide) polymer matrix and an octreotide compound dispersed in the polymer matrix. The microspheres release less than 1% of a total amount of the octreotide compound within 1 hour at 37° C. and pH 7.4. | 2012-01-26 |
20120021019 | CARDIAC STEM CELL POPULATIONS FOR REPAIR OF CARDIAC TISSUE - Method for the isolation, expansion and preservation of cardiac stem cells from human or animal tissue biopsy samples to be employed in cell transplantation and functional repair of the myocardium or other organs. Cells may also be used in gene therapy for treating cardiomyopathies, for treating ischemic heart diseases and for setting in vitro models to study drugs. | 2012-01-26 |
20120021020 | BRANCHED AMPHIPATHIC OLIGO-PEPTIDES THAT SELF-ASSEMBLE INTO VESICLES - The present invention provides branched amphipathic peptides and vesicles formed thereof. The peptides comprise a polar/positively charged C-terminal segment, a branch point, and two hydrophobic N -terminal segments extending from the branch point. The vesicles are formed using a plurality of first and second peptides, wherein the first peptide has a different chain length from the second peptide. When a plurality of the first and second peptides are mixed together, they self-assemble to form small spheres defined by a membrane consisting of an interlocking peptide network bilayer and having a liquid-receiving interior space (i.e., hollow core). In the bi-layer, the respective hydrophobic segments of the peptides form beta-sheet structures having a hydrogen bond-stabilized, anti-parallel orientation in which the opposed sequences interlock to form a zipper-like structure in three dimensions. Thus, the peptide assembly (i.e., vesicle) can be held together at reduced concentrations where lipid vesicles would breakdown. | 2012-01-26 |
20120021021 | METHOD FOR PREPARING PHARMACEUTICAL COMPOSITIONS COMPRISING FINE PARTICLES OF ACTIVE SUBSTANCE - The present invention relates to a method for preparing solid pharmaceutical compositions comprising fine particles of at least one active substance, dispersed on and (or) within a divided solid. This method is characterized in that a solution is formed which comprises at least one active substance in a fluid at supercritical pressure, said solution then being expanded in a chamber under temperature and pressure conditions for which a part of said fluid is in the liquid state at the time of the expansion, said fluid thus expanded being brought into contact with a divided solid in said chamber. | 2012-01-26 |
20120021022 | FOAMABLE SHAVING SUBSTRATE - The present invention provides a personal care product in the form of a foamable shaving substrate that includes a dry substrate that has associated with it a dry shaving material. The shaving material forms a moist hair softening foam when the substrate is exposed to water, facilitating shaving of hair. The foamable shaving substrate may easily be carried anywhere. | 2012-01-26 |
20120021023 | Process For Preparing Silicate Shell Microcapsules - A process for preparing silicate shell microcapsules comprises adding a water reactive silicon compound to an oil in water emulsion, thereby condensing and polymerizing the water reactive silicon compound to form silicate shell microcapsules having a core comprising the oil phase of the said emulsion. The water reactive silicon compound comprises a tetraalkoxysilane and an alkoxysilane having an amino or quaternary ammonium substituted alkyl group. | 2012-01-26 |
20120021024 | DELIVERY SYSTEM FOR ACTIVE COMPONENTS AS PART OF AN EDIBLE COMPOSITION BACKGROUND OF THE INVENTION - A delivery system for inclusion in an edible composition is formulated to have at least one active component with an encapsulating material for delivering the active component upon consumption of the edible composition. | 2012-01-26 |
20120021025 | AQUEOUS COMPOSITION SUITABLE AS SHAMPOO - The present invention concerns aqueous compositions that are suitable as shampoos. The composition comprises an oil and provides an interesting hair treatment, especially an interesting hair treatment targeting damaged hair. | 2012-01-26 |
20120021026 | Dissolvable Fibrous Web Structure Article Comprising Active Agents - The personal care compositions of the present invention are in the form of an Article comprising a dissolvable fibrous web structure. The fibers of the dissolvable fibrous web structure comprise a surfactant; a water soluble polymeric structurant; and a plasticizer. Additionally the ratio of the water soluble water soluble polymeric structurant to the active agent in the fiber is 3.5 or less. | 2012-01-26 |
20120021027 | Cosmetic Composition - A film-forming cosmetic composition that provides superior feel, look, and wear characteristics whilst also delivering UV protection to the skin. The cosmetic composition may be in the form of a water-in-oil emulsion that includes a water compatible film-forming polymer, a sunscreen active, and one or more particles. The foundation provides suitable feel and appearance during application, UV protection, and excellent wear and appearance after application, yet provides flexible, light feel. | 2012-01-26 |
20120021028 | Powdery Composition for Shaping Keratin Fibers and Giving Them Shine - Powdery compositions for temporarily shaping human hair containing 50 to 90 wt. % of water, 0.5 wt. % to 10 wt. % of at least one other liquid having a boiling point higher than 150° C. at a pressure of 1013 mbar, at least one starch substituted with carboxy-(C | 2012-01-26 |
20120021029 | PEPTIDES USED IN THE TREATMENT AND/OR CARE OF THE SKIN AND/OR HAIR AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS - Peptides of general formula (I): | 2012-01-26 |
20120021030 | Liquid Composition Containing Fusiform Particles for Cosmetic Use - A liquid composition for cosmetic use containing 5 to 50 wt % of fusiform particles in a cosmetically acceptable medium, the fusiform particles being made of an organosilicone having a crosslinked polysiloxane structure, and having diameters along major axis L | 2012-01-26 |
20120021031 | DUAL ACTION DENTIFRICE COMPOSITIONS TO PREVENT HYPERSENSITIVITY AND PROMOTE REMINERALIZATION - The invention encompasses combinations of bioactive glass composition and potassium salts that are useful in conjunction with delivery agent such as, for example, toothpastes, mouthwashes, and oral gels. In certain embodiments, the compositions of the invention form a rapid and continuous reaction with body fluids (e.g., saliva) to promote the immediate and long-tem release of Ca and P ions to produce a stable crystalline layer deposited onto and into the dentin tubules for the immediate and long term reduction of dentin hypersensitivity and tooth surface remineralization. | 2012-01-26 |
20120021032 | Pesticide Treatment Of Soils Or Substrates With Sulphur Compounds - In order to replace methyl bromide in all the uses thereof in soil or substrate treatment, the invention relates to the use of at least one sulphur compound having general formula: wherein R represents an alkenyl or alkyl radical, n is equal to 0, 1 or 2, x is a number between 0 and 4 and R′ represents an alkenyl or alkyl radical or, only if n=x=0, a hydrogen or alkali-metal atom. The sulphur compounds (in particular dimethyldisulphide) can be applied according to standard soil treatment methods (by injection, spraying, dripping, sprinkling) and said compounds have no phototoxic effects. | 2012-01-26 |
20120021033 | DISPERSIN B POLYNUCLEOTIDES AND METHODS OF PRODUCING RECOMBINANT DspB POLYPEPTIDES - Isolated nucleic acid sequences and amino acid sequences for soluble, β-N-acetylglucosaminidase or active fragments or variants thereof which promote detachment of bacterial cells from a biofilm are provided. An isolated mutant bacteria which forms biofilm colonies which tightly adhere to surface but which are unable to release cells into the medium or spread over the surface is also provided. In additions, methods are described for modulating detachment of bacterial cells from biofilm by mutating soluble, β-N-acetylglucosaminidase or altering its expression or activity are also provided. Also provided are compositions, methods and devices for preventing, inhibiting and treating bacterial infections. | 2012-01-26 |
20120021034 | STRUCTURED SILVER-MESOPOROUS SILICA NANOPARTICLES HAVING ANTIMICROBIAL ACTIVITY - A submicron structure having a silica body defining a plurality of pores, said silica body further defining an outer surface between pore openings of said plurality of pores; and having at least one silver nanocrystal within said silica body are described. Antimicrobial compositions comprising the submicron structure, and methods of killing or inhibiting growth of microbes using the submicron structure are described. | 2012-01-26 |
20120021035 | Nanoparticles containing plymeric nucleic acid homologs, pharmaceutical composition and articles of manufacture containing same and methods of use thereof - A nanoparticle capable of delivery of an encapsulated molecule into a living cell. The nanoparticle includes an encapsulation media and an isolated nucleic acid homolog sequence. The encapsulation media is primarily polymeric. The nanoparticles release the encapsulated molecule over an extended period of time. Further disclosed are pharmaceutical compositions and articles of manufacture including nanoparticles and methods of preparing and using the nanoparticles. | 2012-01-26 |
20120021036 | COMPOSITE NANOSTRUCTURES AND METHODS FOR MAKING AND USING THEM - The invention provides nanostructures or products of manufacture for use as ex vivo or in vivo composition (e.g., a drug, or a therapeutic, diagnostic or imaging reagent) delivery vehicles. In one aspect, the invention provides nanoparticles comprising several compartments which in unison function as a composite nanostructure. In one embodiment, the nanoparticles of the invention comprise a combination of polymer core/lipid bilayer interface which incorporate covalently attached lipid-vascular targeting ligands. These composite nanoparticles can deliver highly effective and selective payloads for diagnostic, prophylactic or therapeutic applications. | 2012-01-26 |
20120021037 | MEDICAL DEVICES WITH AN ACTIVATED COATING - Implantable medical devices include a substrate having applied thereto a coating including a polymeric material possessing a core and at least one functional group known to have click reactivity. | 2012-01-26 |
20120021038 | COATING COMPOSITION - A wound spacer device comprising multiple beads connected by non-absorbable suture material is disclosed. The device can be applied, for example, by a first responder to an injured individual, or can be applied by a trauma treatment facility, such as a Level 2 medical unit. In typical embodiments the device allows for site-specific controlled elution of an antimicrobial agent, such as Tobramycin, including defined elution over a period of time, such as 48 or 72 hours. | 2012-01-26 |
20120021039 | EXPRESSION OF NEUROPEPTIDES IN MAMMALIAN CELLS - The present application relates to expression constructs capable of securing correct processing of neuropeptides upon expression in mammalian cells, and to mammalian cells secreting correctly processed peptides. One exemplary peptide is galanin. The application also relates to devices containing neuropeptide secreting cells, which devices may be used for the treatment of epilepsy and other disorders of the nervous system. All references cited herein are incorporated by reference. | 2012-01-26 |
20120021040 | THERAPEUTIC AGENT FOR SPINAL CORD INJURIES - Disclosed is a therapeutic agent effective for the fundamental treatment of a spinal cord injury and a demyelinating disease. Specifically disclosed are a therapeutic agent for a spinal cord injury and a therapeutic agent for a demyelinating disease, each of which comprises an HGF protein as an active ingredient. | 2012-01-26 |
20120021041 | TRANSDERMAL DELIVERY - Dosing regimen for transdermal delivery of hormones comprising a 28 day treatment cycle with a fixed treatment interval and a fixed rest interval. | 2012-01-26 |
20120021042 | Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances - A method for preparing amphoteric liposomes loaded with polyanionic active agent as cargo, characterised by admixing an aqueous solution of said polyanionic active agent and an alcoholic solution of one or more amphiphiles and buffering said admixture to an acidic pH, said one or more amphiphiles being susceptible of forming amphoteric liposomes at said acidic pH, thereby to form such amphoteric liposomes in suspension encapsulating said active agent under conditions such that said liposomes form aggregates, and thereafter treating said suspension to dissociate said aggregates. Also disclosed are nucleic acid loaded amphoteric liposomes produced in accordance with the method, wherein said nucleic acids are oligonucleotides and said liposomes are multilamellar. | 2012-01-26 |
20120021043 | Nucleic Acids Comprising formula (NuGlXmGnNv)a and Derivatives Thereof as Immunostimulating Agent/Adjuvant - The present invention relates to nucleic acids of the general formula (I): (N | 2012-01-26 |
20120021044 | Novel Cationic Lipid, A Preparation Method of the Same and A Delivery System Comprising the Same - The present invention provides a novel cationic lipid, a preparation method of the same and a delivery system comprising the same. The cationic lipid of the present invention is used for the preparation of delivery systems of nucleic acids or physiologically active anionic proteins. The cationic lipid of the present invention can be conveniently prepared and purified by a simple process and is therefore economically highly advantageous for industrial-scale production thereof. Further, a nucleic acid or protein delivery system comprising the cationic lipid of the present invention not only significantly improves the intracellular delivery efficiency of desired nucleic acid drugs (such as DNAs, RNAs, siRNAs, antisense oligonucleotides, and nucleic acid aptamers) or anionic proteins having physiological activity, but also is usefully used to augment therapeutic efficacy of nucleic acid or protein drugs due to attenuated cytotoxicity of the delivery system. | 2012-01-26 |
20120021045 | Methods for Inhibiting Cancer Cell Proliferation - The present invention concerns methods of treating cancer and methods of inhibiting cancer cell proliferation, particularly methods of treating breast cancer. | 2012-01-26 |